The phase 3 study was known as the BEACON CRC trial. It evaluated a triple combination of BRAFTOVI, MEKTOVI and ERBITUX (also known as BRAFTOVI triplet) in patients with BRAF V600E mutant mCRC. The ...
Community driven content discussing all aspects of software development from DevOps to design patterns. Here are the most important concepts developers must know when they size Java arrays and deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback